Categories
Longevity

Blood Tests and Longevity: Where Is the Best Value?

A blood test is a measurement system: a relatively inexpensive way of finding cardiovascular risk, metabolic dysfunction, deficiencies, organ abnormalities and changes over time that may justify doing something differently. In that sense, blood testing belongs alongside blood pressure, body composition, fitness and basic preventive medicine, rather than alongside speculative anti-ageing treatments. The useful question […]

Categories
Longevity

DNA Methylation Tests: Can You Really Measure How Fast You Are Aging?

DNA methylation testing may be one of the more interesting developments in the consumer longevity market because, unlike a conventional blood test that tells us what cholesterol, glucose or vitamin D happens to be at a particular moment, an epigenetic clock attempts to use patterns across DNA to estimate something much broader: whether the biological […]

Categories
Non classé

NMN Value analyis

One of Longevity’s Most Interesting Molecules NMN, or nicotinamide mononucleotide, occupies an unusual position in the longevity world because it sits at the intersection of an extremely compelling biological mechanism, a growing collection of human trials, prominent scientists and podcasters who have experimented with it personally, and a regulatory environment that is still trying to […]

Categories
Non classé

Resveratrol value analysis

The Longevity Supplement That Started the Modern Debate Resveratrol is in some respects the original modern longevity supplement: a naturally occurring polyphenol found in grapes, berries, peanuts and other plants that moved from laboratory research into newspapers, podcasts, supplement cabinets and eventually large numbers of human clinical trials, largely because early work suggested that it […]

Categories
Longevity

European Value alternatives to AG1

AG1 Is Excellent. It Is Also a Luxury Product. There is a useful way to think about AG1 that avoids both extremes of the usual online debate: it is neither a miracle powder nor simply an overpriced collection of vitamins, but rather a carefully designed convenience product that combines a large number of nutritional categories […]

Categories
English Markets

China Diversification (2nd quarter 2026)

The central market is whether the world that produced the last forty years of portfolio construction still exists. The answer, increasingly, is: only partially. Modern mercantilism, AI infrastructure, fiscal pressure, war risk, and the re-pricing of national security are becoming market forces in their own right. Bridgewater has described the current moment as two overlapping […]

Categories
English Markets

Risk Building in an AI-Driven Economy (1st Quarter 2026)

1. The World in 2026: A New Economic Regime Two powerful forces are reshaping the global economy at the same time. The first is the return of the state as a central economic actor. Governments are increasingly willing to intervene to secure supply chains, protect strategic industries, and strengthen national economic power. The second is […]

Categories
English Markets

Valuations and Bubbles (4th quarter 2025)

This year of market buoyancy is making investors uneasy. It isn’t only because prices are rising—it’s because they often rise faster than conviction. When central bankers express discomfort, when seasoned macro thinkers warn of bubble dynamics, and when geopolitics increasingly weaponizes currencies and capital flows, investors feel the irresistible urge to respond. But as Buffett reminds […]

Categories
English Markets

Staying Focused in Essential Financial Goals (3rd quarter 2025)

Staying the Course Amidst Noise The financial world is entering yet another phase of turbulence. The headlines of this quarter revolve around three major forces: uncertainty around the US dollar, the escalation of new global conflicts, and the relentless march of artificial intelligence. Each has the potential to unsettle markets, but none should deter investors […]

Categories
English Markets

Contrarian investing in April (2nd quarter 2025)

Contrarian investing, valuation